What is Aurealis Pharma?
Aurealis Pharma is a biotechnology firm specializing in the development of multi-target cell and gene therapies. Their core focus lies in addressing critical unmet medical needs across several therapeutic areas, including chronic wounds, oncology, and inflammatory diseases. The company's proprietary 4-in-1 therapy platform is engineered to tackle complex, multifactorial conditions, demonstrating a commitment to advancing regenerative medicine and improving patient outcomes through rigorous scientific research and strategic clinical development.
How much funding has Aurealis Pharma raised?
Aurealis Pharma has raised a total of $10.8M across 3 funding rounds:
Angel/Seed
$1.8M
Angel/Seed
$3.3M
Series A
$5.8M
Angel/Seed (2014): $1.8M with participation from Tekes
Angel/Seed (2016): $3.3M led by Finnvera plc
Series A (2017): $5.8M supported by Finnvera plc and Tekes
Key Investors in Aurealis Pharma
Finnvera plc
Finnvera plc is a specialized financing company owned by the State of Finland, providing crucial financing and guarantees for Finnish enterprises, particularly in their growth and internationalization phases. As Finland's official Export Credit Agency, they play a vital role in supporting export risks and strengthening the competitiveness of Finnish businesses.
Tekes
Tekes, now Business Finland, is a Finnish funding agency for technology and innovation. They support researchers and companies in commercializing innovative ideas, providing funding and guidance to transform concepts into successful market ventures.
Finnvera plc
Finnvera plc, the Finnish state-owned export credit agency, offers comprehensive financing solutions and risk guarantees to support the growth and international expansion of Finnish companies, thereby bolstering the national economy.
What's next for Aurealis Pharma?
With the recent major enterprise-level funding, Aurealis Pharma is poised for significant expansion and advancement. The strategic investment will likely fuel the progression of their innovative therapy platform through critical clinical trial phases and potential market entry. This capital will also support scaling manufacturing capabilities and expanding research and development efforts, reinforcing their position in the competitive biotech landscape and driving towards their goal of delivering impactful treatments for challenging diseases.
See full Aurealis Pharma company page
